Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 485 | 105 | 374 |
| Samples | 219 | 59 | 156 |
| Peptides | 192 | 49 | 144 |
Function
MKNK2 · MAPK interacting serine/threonine kinase 2
This gene encodes a member of the calcium/calmodulin-dependent protein kinases (CAMK) Ser/Thr protein kinase family, which belongs to the protein kinase superfamily. This protein contains conserved DLG (asp-leu-gly) and ENIL (glu-asn-ile-leu) motifs, and an N-terminal polybasic region which binds importin A and the translation factor scaffold protein eukaryotic initiation factor 4G (eIF4G). This protein is one of the downstream kinases activated by mitogen-activated protein (MAP) kinases. It phosphorylates the eukaryotic initiation factor 4E (eIF4E), thus playing important roles in the initiation of mRNA translation, oncogenic transformation and malignant cell proliferation. In addition to eIF4E, this protein also interacts with von Hippel-Lindau tumor suppressor (VHL), ring-box 1 (Rbx1) and Cullin2 (Cul2), which are all components of the CBC(VHL) ubiquitin ligase E3 complex. Multiple alternatively spliced transcript variants have been found, but the full-length nature and biological activity of only two variants are determined. These two variants encode distinct isoforms which differ in activity and regulation, and in subcellular localization. [provided by RefSeq, Aug 2011].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 172 amino-acid changes on canonical ENST00000250896 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MKNK2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MKNK2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 9/40 22% | 0/0 0% |
| Chordoma | 2/7 29% | 1/13 8% |
| Hodgkins Lymphoma | 2/16 12% | 2/122 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 7/612 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Plasma Cell Myeloma | 1/44 2% | 2/305 1% |
| Colorectal Carcinoma | 6/143 4% | 23/3239 1% |
| Gastric Carcinoma | 0/74 0% | 13/1809 1% |
| Neuroendocrine Tumour | 4/154 3% | 1/577 0% |
| Melanoma | 2/210 1% | 12/1899 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 4/1390 0% |
| Hepatocellular Carcinoma | 0/46 0% | 12/2210 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 8/2534 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Other Solid Cancers | 0/94 0% | 6/1515 0% |
| Ovarian Carcinoma | 4/109 4% | 0/998 0% |
| Kidney Carcinoma | 2/85 2% | 5/1862 0% |
| Head and Neck Carcinoma | 1/85 1% | 5/1574 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Pancreatic Carcinoma | 0/89 0% | 5/1611 0% |
| Neuroblastoma | 4/87 5% | 0/1331 0% |
Mutation Distribution
Where MKNK2 is mutated · all tissues, split by cell line vs tissue
How many mutations in MKNK2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 485 mutations in MKNK2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|